Tuesday April 8th 2014
Immunoadjuvant ISG15 enhances human papillomavirus
Author- Inovio Pharmaceuticals
Link To Conference Info
The deadline for submission of late-breaking abstracts was Monday, January 27. Abstracts detailing highly significant and timely findings in any area of cancer research that were not available at the time of the regular abstract deadline were considered by the AACR Annual Meeting Program Committee for presentation at the AACR Annual Meeting 2014. Only those abstracts that were deemed to be of high scientific priority have been accepted. A special subcommittee of the Program Committee evaluated the merit of late-breaking abstracts. Each late-breaking abstract must have been sponsored by an AACR member.
Authors who submitted abstracts confirm that they have not previously published these data, that they have not previously presented them at a large national annual scientific meeting, and that they are not planning to present or publish them prior to the dates of the AACR Annual Meeting 2014. Each abstract should have contained: (a) an introductory sentence indicating the purposes of the study; (b) a brief description of pertinent experimental procedures; (c) a summary of the new, unpublished data; and (d) a statement of the conclusions. Authors must accept sole responsibility for the statements in their abstracts. Abstract submitters were asked to carefully proofread to avoid errors in the published literature and to use American English spelling throughout. For more information regarding American English spelling, please refer to Scientific Style and Format:
Melanoma Skin Cancer is less common, but more dangerous than other types of skin cancer. If you or your loved one has been diagnosed with Melanoma Skin Cancer, then consult with Dr. Speron online at www.chicagoskincancersurgery.com
ReplyDelete